Skip to main content
NewslettersWatchlist

Vaxart Inc(VXRT-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.9500
Day High1.0400
Open:1.0400
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stock Index Futures Muted as Weak China Trade Data Weighs on Sentiment
Motley Fool
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
Motley Fool
3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street
Motley Fool
2 Struggling Stocks to Avoid Right Now
Globe Newswire
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
Globe Newswire
Vaxart Appoints W. Mark Watson to its Board of Directors
Globe Newswire
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
Motley Fool
Could This Unknown Stock Beat Moderna in 2023?
Globe Newswire
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
Globe Newswire
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
Globe Newswire
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
Globe Newswire
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
Globe Newswire
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
Globe Newswire
Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model
Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Globe Newswire
Vaxart to Host Investor Q&A Webcast
Globe Newswire
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Motley Fool
Better Buy: Novavax vs. Vaxart
Globe Newswire
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
Motley Fool
Stock Market Plunge: 2 Stocks to Avoid Right Now
Globe Newswire
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
Globe Newswire
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
Motley Fool
Can This 1 Thing Hurt Vaxart?
Globe Newswire
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
Barchart
Now is the Time to Go Long on These 3 Biotech Stocks
Motley Fool
2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?
Globe Newswire
Vaxart to Present at World Vaccine Congress Washington 2022 on April 20
Business Wire
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Motley Fool
Is Vaxart the Next Moderna?
Motley Fool
Is It Too Late to Buy Vaxart Stock?
Motley Fool
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
Globe Newswire
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Profile

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus. Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Francisco, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.